EAM
BMRN icon

EverPoint Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

EverPoint Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-70,400
Closed -$5.48M – 414
2016
Q2 		$5.48M Buy
+70,400
New +$5.98M 0.11% 219

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's BMRN Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2016: 405,000 shares worth $33.5M. The stake represents 0.62% of the portfolio and ranks #36 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in BMRN as recently as Q1 2015.

EverPoint Asset Management first reported a position in BMRN in Q2 2014 and has held it in 5 quarters since. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

  • EverPoint Asset Management held 405,000 shares of BioMarin Pharmaceuticals worth $33.5M as of Q4 2016.
  • BioMarin Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
  • BioMarin Pharmaceuticals made up 0.62% of EverPoint Asset Management's portfolio in Q4 2016, its #36 holding.
  • EverPoint Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 5 quarters since.
  • 415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.